News
-
WEBINAR | Haemoglobin Disorders and EU Health Policies, 21 September 2023
Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The series will encompass all EU legislative files directly or indirectly…
Read More » -
IN THE SPOTLIGHT | Explore Our Latest Work in the TIF Newsletter, August Edition
The remarkable collaborations and activities carried out in the past two months have been truly invigorating, and we eagerly anticipate the initiation of upcoming noteworthy endeavours. In this issue, read…
Read More » -
CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS
The approval was based on interim results from the pivotal phase 3 COMMANDS trial (ClinicalTrials.gov Identifier: NCT03682536) that evaluated the efficacy and safety of luspatercept in 356 patients with anemia due to international…
Read More » -
TIF European Health Policy Webinar Series | 21 September 2023
Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The series will encompass all EU legislative files directly or indirectly…
Read More » -
PUBLICATIONS | Nutrition Guide for Patients with Thalassemia & PKD
Nutrition holds a significant position in the lives of individuals afflicted with thalassaemia and other hereditary anaemias. As part of its enduring commitment to generating guidelines and educational materials for…
Read More » -
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
The Conference, organized in collaboration with the Federation of Malaysia Thalassaemia Societies, the Malaysia Hematology Society and the Malaysian Association of Paediatric Haematology & Oncology, and with the support of…
Read More » -
DRUGS | EU Pulls Authorization of Adakveo for Sickle Cell Disease
The decision comes after the Committee on Medicinal Products for Human Use (CHMP) recommended in May 2023 to pull the approval following a review of additional Phase III data. The EC’s decision…
Read More » -
COLD AGGLUTININ DISEASE | Enjaymo Improved Life Quality in Patients for 2.5 Years
“Enjaymo provides sustained and durable treatment benefits in chronic CAD, including a continued meaningful impact on patient quality of life in the long term,” the researchers wrote. However, these benefits…
Read More » -
NEW SURVEY | Thalassaemia Care Delivery From A Patient Perspective
The survey focuses on capturing the patient perspective on thalassaemia care delivery in various countries. This initiative by TIF aims to gather valuable insights into the experiences and challenges faced…
Read More » -
NEWS | WHO Updates Essential Medicines List, Adds New Medicines for Thalassaemia
Until recently, the WHO EML recommended only deferoxamine for iron chelation, limiting patients’ access to other crucial pharmacological alternatives for the effective management of their condition. Since 2019, the Thalassaemia…
Read More »